# Endovascular treatment for acute ischemic stroke; the use of periprocedural heparin or antiplatelet agents

Submission date	Recruitment status	[] Prospec		
01/11/2017	No longer recruiting	[X] Protoco		
<b>Registration date</b> 06/12/2017	<b>Overall study status</b> Completed	[X] Results		
Last Edited 13/02/2025	<b>Condition category</b> Circulatory System	[_] Individu		

- ctively registered
- ol
- cal analysis plan
- Jal participant data

#### Plain English summary of protocol

Background and study aims

When a blood clot blocks the flow of blood to the brain an ischemic stroke occurs. When this happens, the bloodstream leading to the blocked brain arteries can be entered using very small tubes (catheters) and mechanical devices (retrievable stents). By means of this procedure (intraarterial treatment; IAT) the clot can be removed and the blocked brain areas can be reopened. This procedure has been proven safe and effective when performed within 6 hours after onset. However, despite clot removal a considerable proportion of patients do not recover. This is for a major part due to a disturbed circulation of the capillaries (Incomplete microvascular reperfusion; IMR). Antiplatelet drugs and heparin may reduce IMR. The aim of this study is to assess the effect of acetylsalicylic acid (ASA) and unfractionated heparin (UFH), alone or in combination, in patients with a stroke undergoing IAT.

Who can participate?

Patients aged 18 or older with acute ischemic stroke undergoing IAT

#### What does the study involve?

Participants are randomly allocated to be treated with either ASA, UFH, both or neither. When a patient is allocated to receive ASA a loading dose (a large initial dose) is given. When allocated to UFH, patients receive a loading dose and either a low or moderate continuous infusion for 6 hours. Every participant undergoes a brain scan of the cerebral vessels to assess the rate of recanalization (restoration of blood flow) at 24 hours and at 5-7 days to assess final infarct volume (the dead tissue resulting from lack of blood supply). During the hospital stay several blood samples are taken to look for blood clotting abnormalities. After 90 days, participants are contacted by telephone to check on their general condition.

What are the possible benefits and risks of participating?

There is a potential benefit of an improved functional outcome and a low risk, which includes the risk of bleeding inside the skull. The potential benefits of ASA and UFH are expected to outweigh the limited risks of harm of these study treatments.

Where is the study run from?

The study will run in about 19 stroke intervention centers in the Netherlands. The lead center is the Erasmus Medical Center.

When is the study starting and how long is it expected to run for? May 2017 to April 2022

Who is funding the study? 1. Dutch Heart Foundation (Netherlands) 2. Dutch Brain Foundation (Netherlands) 3. Stryker (USA)

Who is the main contact? Rob van de Graaf, MD

Study website http://www.mrclean-med.nl

## **Contact information**

**Type(s)** Scientific

**Contact name** Mr Rob van de Graaf

#### **Contact details**

Erasmus MC, University Medical Center 's Gravendijkwal 230 Departments of Neurology and Radiology Room Ee 2240. Rotterdam Netherlands 3000 CA

## Additional identifiers

**EudraCT/CTIS number** 2017-001466-21

#### **IRAS number**

**ClinicalTrials.gov number** Nil known

Secondary identifying numbers NL61364.078.17

# Study information

#### Scientific Title

Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands: the effect of periprocedural MEDication: heparin, antiplatelet agents, both or neither

#### Acronym

MR CLEAN-MED

#### **Study objectives**

The use of unfractionated heparin and acetylsalicylic acid, alone, or in combination increases functional outcome within 3 months in patients who undergo intra-arterial treatment for an acute ischemic stroke caused by a confirmed intracranial large vessel occlusion of the anterior circulation.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Medisch Ethische Toetsings Commissie Erasmus MC (Medical Ethical Committee Erasmus MC), 09 /10/2017, ref: MEC-2017-366

#### Study design

Multicenter phase III clinical trial with randomized treatment allocation, open-label treatment and blinded endpoint assessment (PROBE), with a 2x3 factorial design

#### Primary study design

Interventional

**Secondary study design** Randomised controlled trial

### Study setting(s)

Hospital

**Study type(s)** Treatment

#### Participant information sheet

Not available in web format yet, please use the contact details to request a patient information sheet.

#### Health condition(s) or problem(s) studied

Acute ischemic stroke due to an intracranial large vessel occlusion of the anterior circulation

#### Interventions

Patients will be randomized either to receive acetylsalicylic acid, unfractionated heparin, both or none during intra-arterial treatment. The randomization procedure will be computer- and webbased, permuted blocks. Backup by telephone. Randomization will take place according to the 2x3 factorial PROBE design. Acetylsalicylic acid will be administered intravenously, in a loading dose of 300 mg. Unfractionated heparin will be administered intravenously in a low dose (loading dose of 5000 IU followed by 500 IU/hour x 6 hours) or moderate dose (loading dose of 5000 IU followed by 1250 IU/hour x 6 hours). Both the IV acetylsalicylic acid and heparin treatment should be started prior to groin puncture when no IVT is administered or directly after /when the IV alteplase has been stopped.

Every participant will undergo a brain scan of the cerebral vessels to assess rate of recanalization at 24 hours and at 5-7 days to assess final infarct volume. During hospital stay several blood samples will be drawn to look for blood clotting abnormalities. After 90 days, participants are approached by telephone to check on their general condition.

#### Intervention Type

Drug

Pharmaceutical study type(s)

Not Applicable

**Phase** Phase III

#### Drug/device/biological/vaccine name(s)

Unfractionated heparin, acetylsalicylic acid

#### Primary outcome measure

Functional outcome, measured by the modified Rankin Scale (mRS) at 90 days. Assessment of outcome on the mRS will be performed by independent assessors, blinded to the allocated and actually received treatment. Their assessment will be based on standardized reports of a telephone interview by trained research personnel who are not aware of treatment allocation.

#### Secondary outcome measures

1. Reperfusion grade, measured by the extended treatment in cerebral ischaemia (eTICI) score on final angiography of IAT

2. Symptomatic intra-cranial hemorrhage, according to the Heidelberg criteria

3. Clinical stroke severity, measured by the National Institutes of Health Stroke Scale score at 24 hours, and 5-7 days after randomization, or at discharge

4. Final infarct volume, measured on cranial non-contrast CT or MRI in a subset of 600 patients at 5-7 days after randomization. Infarct size at day 5-7 will be compared with plain CT and perfusion CT results (if available) at baseline

5. Dichotomization of functional outcome, measured by the modified Rankin Scale (mRS) at 90 days

6. Mortality at 90 days

Overall study start date

01/05/2017

Completion date 30/04/2022

# Eligibility

Key inclusion criteria

1. A clinical diagnosis of acute ischemic stroke

2. Caused by a intracranial large vessel occlusion of the anterior circulation: distal intracranial carotid artery or middle (M1/proximal M2) cerebral artery, confirmed by neuro-imaging (CTA or MRA)

- 3. CT or MRI ruling out intracranial hemorrhage
- 4. Intra-arterial treatment (groin puncture) possible within 0-6 hours
- 5. A score of at least 2 on the NIH Stroke Scale
- 6. Age of 18 years or older
- 7. Written informed consent (deferred)

#### Participant type(s)

Patient

#### Age group

Adult

#### Lower age limit

18 Years

#### Sex

Both

Target number of participants

1500

#### Total final enrolment

663

#### Key exclusion criteria

1. Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i. e. mRS >2

2. Treatment with IV alteplase despite the following contra-indications for IV alteplase:

2.1. Cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of recent infarction on neuroimaging

2.2. Previous intracerebral hemorrhage within the previous 3 months

- 2.3. INR exceeding 1.7
- 2.4. Prior use of direct oral anticoagulant (DOAC)
- 2.5. IV alteplase infusion >4.5 hours after symptom onset
- 3. Contra-indications for ASA/unfractionated heparin, for instance: allergy, recent surgery,
- heparin induced thrombocytopenia
- 4. INR exceeding 3.0
- 5. Thrombocyte count <100^9/L
- 6. Participation in trials other than current and MR ASAP

#### Date of first enrolment

01/11/2017

#### Date of final enrolment

01/11/2021

### Locations

**Countries of recruitment** Netherlands

**Study participating centre Erasmus MC, University Medical Center** Rotterdam Netherlands 3000 CA

**Study participating centre Academic Medical Center** Amsterdam Netherlands 1005 AZ

**Study participating centre University Medical Center Utrecht** Utrecht Netherlands 3508 GA

**Study participating centre Maastricht University Medical Center** Maastricht Netherlands 6202 AZ

### Sponsor information

**Organisation** Erasmus MC, University Medical Center

**Sponsor details** Erasmus MC, University Medical Center Department of Neurology Room Ee2240 Rotterdam Netherlands 3000 CA

**Sponsor type** Charity

ROR https://ror.org/018906e22

### Funder(s)

Funder type Charity

**Funder Name** Hartstichting

Alternative Name(s) Heart Foundation

**Funding Body Type** Private sector organisation

**Funding Body Subtype** Trusts, charities, foundations (both public and private)

**Location** Netherlands

Funder Name Hersenstichting

Alternative Name(s) Hersenstichting Nederland, Nederlandse Hersenstichting

**Funding Body Type** Private sector organisation

**Funding Body Subtype** Trusts, charities, foundations (both public and private)

**Location** Netherlands **Funder Name** Stryker

Alternative Name(s) Stryker Corporation

**Funding Body Type** Private sector organisation

**Funding Body Subtype** For-profit companies (industry)

**Location** United States of America

### **Results and Publications**

#### Publication and dissemination plan

Additional documents (study protocol/statistical analysis plan) will be available approximately 1 year after the first patient's inclusion. Planned publication of results in a high-impact peer reviewed journal.

#### Intention to publish date

01/11/2023

#### Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

#### IPD sharing plan summary

Data sharing statement to be made available at a later date

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient- facing?
Results article		28/02 /2022	04/03 /2022	Yes	No
<u>Other</u> publications	Study progress abstract European Stroke Organisation Conference 2021	03/09 /2021	29/03 /2023	Yes	No
<u>Protocol</u> article		14/07 /2020	13/02 /2025	Yes	No